The following is a summary of "Worsening disease severity as measured by I-SEE associates with decreased treatment response ...

Morgan Stanley has initiated Celldex Therapeutics (NASDAQ:CLDX) at overweight saying that barzolvolimab (barzol), its asset ...

Had cash of $33.1M as of December 31, 2024, up from $19.3M at the end of FY23. Anticipates that existing cash reserves and proceeds will be ...

The incidence and prevalence of eosinophilic esophagitis in the United States are higher than previously reported, indicating increased disease burden, according to a poster presented here. EoE can ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company ...

Only two cases of chronic hiccups tied to eosinophilic esophagitis have previously been reported, the man's doctors say.

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an announcement. Eupraxia Pharmaceuticals announced its fourth quarter 2024 financial results, ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

Bone density can be assessed by dual-energy bone densitometry with specific X-rays, CT-based absorptiometry, quantitative ...